

Brighter

# Interim report

April - June 2021





# Table of Contents.

Table of Contents. ....	2
April – June 2021. ....	3
January - June 2021. ....	4
Financial overview. ....	4
Significant events during the quarter. ....	5
Significant events after the end of the quarter. ....	6
CEO statement. ....	6
Comments on the financial results. ....	10
Submission of interim report. ....	16
Financial statements. ....	17
Consolidated statement of comprehensive income. ....	17
Consolidated statement of financial position. ....	18
Consolidated statement of changes in equity. ....	20
Consolidated statement of cash flows. ....	21
Parent Company income statement. ....	22
Parent Company balance sheet. ....	23
Notes. ....	25
About Brighter. ....	31



## April – June 2021.

- Net sales amounted to SEK 1,599 thousand (2,128).
- Operating result amounted to SEK -51,658 thousand (-46,362).
- Earnings before tax amounted to SEK -73,063 thousand (-53,765).
- Operating cash flow amounted to SEK -34,229 thousand (-39,113)
- Earnings per share, before and after dilution amounted to SEK -0.20 (-0.17).

Operating result for the period amounted to SEK -51,658 thousand (-46,362). Among the reasons for the weaker result was increased amortization of capitalized development. Depreciation was SEK -14,889 thousand (-6,688). Brighter contributed SEK -13,314 thousand to the operating result. The rest refers to Camanio and Nectarine Health.

Average headcount during the quarter (Full Time Equivalents – FTE) reached 109. The number of FTE being 74 (70) employees and 35 consultants.

The staff cost amounted to SEK -18,373 thousand (-18,541) of which SEK -8,039 thousand relates to Brighter and the rest refers to Camanio and Nectarine Health.



## January - June 2021.

- Net sales amounted to SEK 3,785 thousand (3,840).
- Operating result amounted to SEK -101,158 thousand (-84,409).
- Earnings before tax amounted to SEK -126,118 thousand (-91,338).
- Operating cash flow amounted to SEK -84,543 thousand (-104,575).
- Earnings per share, before and after dilution amounted to SEK -0.40 (-0.67).

Operating result for the period amounted to SEK -101,158 thousand (-84,409). Brighter contributed SEK -79,341 thousand to the operating result and the rest refers to Camanio and Nectarine Health. Part of the reason for the weaker result was the addition to the Group of Nectarine Health in Q1 2020, but mainly it refers to increased amortization of capitalized expenditure for development work in Brighter AB. Depreciation and amortization in total were SEK -29,936 thousand (-13,210) of which SEK -26,628 thousand refers to Brighter and the rest refers to Camanio and Nectarine Health.

Average headcount during the period (Full Time Equivalents – FTE) reached 114. The number of FTE being 79 (70) employees and 35 consultants.

The staff cost amounted to SEK -37,560 thousand (-33,439) of which SEK -16,469 thousand relates to Brighter and the rest refers to the operations in Camanio and Nectarine Health.

## Financial overview.

SEK thousands	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec 2020	Jan-Dec 2019
Net sales	1,599	2,128	3,785	3,840	12,286	2,398
Operating result	-51,658	-46,362	-101,158	-84,409	-230,577	-79,809
Net financial items	-21,405	-7,403	-24,960	-6,929	-13,575	-9,875
Earning before tax	-73,063	-53,765	-126,118	-91,338	-244,152	-89,685
Total assets	317,934	379,314	317,934	379,314	338,917	255,664
Equity per share (SEK)	0.72	1.60	0.72	1.60	1.23	1.67
Equity ratio to total assets	78%	87%	78%	87%	74%	81%

For definitions, see note 10.



## Significant events during the quarter.

- Patent to safely combine MDD and IVDD functionality into one unit is granted in Brazil.
- Brighter makes progress with the user experience test of the Diabetes Management Solution Actiste.
- Brighter initiates commercial partnership with DiapointME in the United Arab Emirates.
- Brighter's subsidiary Camanio launched innovative pilot project with Tomelilla Municipality.
- Compatibility with New insulins opens up new market opportunities for Brighter's Actiste<sup>®</sup>
- Brighter and Prime Medical Center in Dubai enter into commercial partnership Regarding Actiste.
- Brighter and Al Zahra hospital in Dubai entered into a commercial partnership regarding Actiste.
- Change in Brighter Management as Ann Zetterberg resigns as CFO and hands over to Julie Silber as acting CFO.
- Brighter's subsidiary Camanio wins allocation decision for stationary security alarms with KSON (The Municipal association for health care in Norrtälje).
- Brighter enters a Proof-of-Concept collaboration with Chronos Care (Chronos Labs AB) to verify Brighter's Actiste<sup>®</sup> service and evaluate the potential for future commercial collaboration in Sweden.
- Brighter's Auditor, in the Audit Report for the Fiscal Year 2020, specifically recommends the general meeting not to grant the former CEO Henrik Norström and the former chairman Truls Sjöstedt discharge from liability for the financial year 2020.



## Significant events after the end of the quarter.

- Brighter carries out a private placement of SEK 5 million and will use the cash to repay debt to those investors. Brighter's share capital will increase by SEK 244,858.00 and the number of shares will increase by 4,897,160 shares, to 352,215,593 shares.
- Brighter's subsidiary Nectarine Health expands user friendly trial in U.S.
- Brighter appoints Erik Lissner as interim CEO.
- Brighter held the Annual General Meeting on the 21st of July. The AGM reelected board members Habib El Assaad, Åsa Sjöblom Nordgren, Christer Trägårdh and Emilie Erhardt Winiarski and added Karin Börjesson O'Connor and Clas Lindbergson to the board as new members. Christer Trägårdh was elected chairman. The AGM voted according to the auditor's recommendation regarding discharge of liability for the board and CEO. The previous CEO Henrik Norström and the previous chairman Truls Sjöstedt did not receive the AGM's discharge from liability, due to negligence in connection with the lending of company funds. All other members of the board received discharge of liability.
- Brighter entered into commercial collaboration agreement with VivBon AB in Sweden for the Actiste® portfolio.
- Both Actiste® (with insulin injection) and Actiste® Mini, received type approval for the radio transmission element in the device (telecommunication) from the Qatari Communications Regulatory Authority.
- Brighter received clarification from the United Arab Emirates Ministry of Health and Prevention regarding data storage and processing in Actiste® Diabetes Management Solution.
- Brighter commences legal action against Unwrap Finance Nordic AB regarding company funds invested in debt securities in March/April 2020 (by the previous CEO and former chairman).

## CEO statement.

A quarter characterized by several important commercial milestones for Brighter and its subsidiaries.

During the second quarter, we achieved several important commercial milestones for Actiste®, Camanio and Nectarine Health.



At the beginning of the quarter, we announced that Brighter's User Experience collaboration with two Swedish health centers, one in Halland and the other in Västra Götaland, is on track and continues to strengthen our position in the Swedish market. This collaboration will provide valuable patient insights that will further support the Actiste® portfolio's commercialization. Brighter aims to present a summary of this project at the end of this year.

Later in the quarter, we entered a Proof-of-Concept collaboration with Chronos Care (Chronos Labs AB) to verify Brighter's Actiste® service and evaluate the potential for future commercial collaboration in Sweden with physicians and nurses who work with Chronos Care and its patients.

In Brazil we received a patent for Actiste® to safely combine Medical Device Directive (MDD) and In-Vitro Diagnostics Directive (IVDD) functionality into one unit. This patent is a key step towards bringing the benefits of our diabetes-care solution to Brazil which will be an important future market for Brighter.

I am very pleased with the progress that the Actiste® portfolio made in the United Arab Emirates (UAE) this quarter. We entered a new sales channel with a commercial partnership with DiapointME, a diabetes-oriented digital platform and e-commerce site in the UAE that will market and sell Actiste® and Actiste Mini® on their platform. We have continued our mission to improve the lives of people living with diabetes in the region by entering into two additional commercial partnerships with Al Zahra hospital and Prime Medical Center for Actiste® and Actiste® Mini in Dubai. Both are direct sales channels to reach potential Actiste® users in the UAE. Sales of subscriptions through Brighter's local subsidiary will commence once all necessary data storage and telecommunications product and market preparations are completed in the UAE.

In June, we announced that our Actiste® device is compatible with a wider variety of insulin cartridges and now can support insulin cartridges from Sanofi and BIOTON S.A. (SciGen Pte. Ltd. – the exclusive distributor of BIOTON products, excluding Poland) This opens additional markets with new revenue opportunities worldwide for Actiste®.

Momentum continued across our subsidiaries as Nectarine Health initiated discussions with several potential partners in the United States for its AI-based well-being technology, Nectarine Health™ at Home, that focuses on digital care services for the elderly.

Camano also had great commercial success in the quarter, starting with the launch of a pilot project in Tomelilla municipality that aims to digitalize elderly care through its digital platform, Camano SmartCare. At the end of the quarter, Camano won a tender to be a supplier of stationery care alarms and alarm reception with Norrtälje Municipality. This marks Camano's first customer within the Adda framework agreement and includes delivery of a digital care platform for alarm reception / management as well as hardware, in the form of care alarms, sensors, and portable alarm buttons. This is a huge milestone for Camano.



After the quarter we reached some important milestones that I would like to highlight. In Qatar, both Actiste® (with insulin injection) and Actiste® Mini, received type approval for the radio transmission element in the device (telecommunication) from the Qatari Communications Regulatory Authority. This approval is another significant commercialization achievement for the Actiste® portfolio and we remain focused on completing all the remaining commercialization preparations to bring Brighter's diabetes management platform to patients in need in the region. Additionally, Brighter expanded its sales channels in Sweden with a commercial collaboration with VivBon AB, a Swedish service provider that offers a wide range of personalized services and solutions for seniors and their relatives, to sell Brighter's Actiste® and Actiste® Mini portfolio for diabetes management. In the beginning of this month, we received a very welcome preliminary assessment from the United Arab Emirates (UAE) Ministry of Health and Prevention that Brighter's Actiste® device is considered to fall within the "simple device" categorization. Brighter is evaluating the implications of this development and will communicate in due course its assessment of how this affects go-to-market prospects under previously announced partnership agreements for the United Arab Emirates (UAE). This is an important commercialization milestone for Brighter and we remain focused on providing services for patients and healthcare providers in this area.

Lastly but not least, I am pleased to welcome Erik Lissner to Brighter as the new interim CEO, as announced on the 20<sup>th</sup> of July 2021. Erik brings extensive experience from within the MedTech sector and is a strong leader who has successfully driven change and improved the performance of various businesses throughout his career. I am confident that Erik is the right person to bring Brighter into the company's next chapter and that together with the Brighter team, he will continue to run the company towards new upcoming milestones. I look forward to remaining in the company and contributing to the progress in my new role as Chairman of the Board.

Christer Trägårdh – Chairman of the Board

I am honored to join Brighter during this pivotal and exciting time in the company's history. I believe that Brighter is in a position to evolve into a leader in diabetes management as a service and to continue the goal of expanding data-driven healthcare in diabetes globally.

On behalf of the Board and the entire Brighter team I thank you for your continued support of Brighter's efforts to contribute to improve health outcomes and wellbeing and facilitate increased efficiency throughout healthcare systems around the world.

Erik Lissner – Acting CEO







## Comments on the financial results.

### Financial results for April-June 2021.

#### Income.

Net sales were 1,599 thousand (2,128). Other operating income amounted to SEK 430 thousand (509) for the period. Capitalized expenditure for development were SEK 15,086 thousand (18,895).

#### Operating result.

Operating result for the period amounted to SEK -51,658 thousand (-46,362). Among the reasons for the weaker result was increased amortization of capitalized development. Depreciation was SEK -14,889 thousand (-6,688). Brighter contributed SEK -13,314 thousand to the operating result. The rest refers to Camanio and Nectarine Health.

Average headcount during the quarter (Full Time Equivalent – FTE) reached 109. The number of FTE being 74 (70) employees and 35 consultants.

The staff cost amounted to SEK -18,373 thousand (-18,541) of which SEK -8,039 thousand relates to Brighter and the rest refers to Camano and Nectarine Health.

Other external costs decreased and amounted to SEK -29,338 thousand (-41,339) of which SEK -26,128 thousand relates to Brighter and the rest refers to Camanio and Nectarine Health.

#### Cash flow.

At the start of the quarter, the Group had cash of SEK 43,282 thousand (78,483), decreasing to SEK 15,620 thousand (23,470) by the end of period.

Cash flow from operating activities amounted to SEK -34,229 thousand (-39,113). Investments amounted to SEK -15,053 thousand (-25,068) of which investment of SEK -15,053 thousand (-22,570) in intangible assets and SEK 0 (2,498) thousand in property, plant and equipment.

Financing of SEK 27,662 thousand (9,168) after costs was raised through conversion of warrants into shares during the period.

Total cash flow for the period amounted to SEK -27,662 thousand (-55,013)

### Financial results for January-June 2021.

#### Income.

Net sales were SEK 3,785 thousand (3,840). Other operating income amounted to SEK 2,556 thousand (1,038). Capitalized production costs were SEK 28,662 thousand (27,536).



## Operating result.

Operating result for the period amounted to SEK -101,158 thousand (-84,409). Brighter contributed SEK -79,341 thousand to the operating result and the rest refers to Camanio and Nectarine Health. Part of the reason for the weaker result was the addition to the Group of Nectarine Health in Q1 2020, but mainly it refers to increased amortization of capitalized expenditure for development work in Brighter AB. Depreciation and amortization in total were SEK -29,936 thousand (-13,210) of which SEK -26,628 thousand refers to Brighter and the rest refers to Camanio and Nectarine Health.

Average headcount during the period (Full Time Equivalents – FTE) reached 114. The number of FTE being 79 (70) employees and 35 consultants.

The staff cost amounted to SEK -37,560 thousand (-33,439) of which SEK -16,469 thousand relates to Brighter and the rest refers to the operations in Camanio and Nectarine Health.

Other external costs decreased and amounted to SEK -58,714 thousand (-67,924) of which SEK -47,262 thousand relates to Brighter and the rest refers to the operations in Camanio and Nectarine Health.

## Financial position.

Capitalized expenditure for development work during the period amounted to SEK 28,662 thousand (27,536), of which SEK 10,303 thousand relates to the development in Brighter, SEK 11,730 thousand relates to Nectarine Health and SEK 6,629 thousand relates to Camanio. Book value of capitalized expenditure totaled SEK 166,272 thousand (182,650). Patents and trademarks were SEK 7,993 thousand (6,613). The total intangible assets are SEK 184,270 thousand (199,270) of which SEK 100,750 thousand relates to Brighter and the rest to Camanio and Nectarine Health.

Book value of property, plant and equipment totaled SEK 30,652 thousand (34,199) of which equipment tools and installations in use SEK 18,161 thousand (16,087). Also, right-of-use assets relating to the rental agreements and leasing agreement for other assets held by the Group were SEK 12,491 thousand (18,112).

Financial assets mainly consist of shares of 9,11% ownership in Accumbo AB with a book value of SEK 11,095 thousand.

Inventory amounted to SEK 16,717 thousand (17,222) of which SEK 14,125 thousand relates to Brighter and the rest to Camanio.

Other current receivables, SEK 45,553 thousand (81,788) include pre-payments to Sanmina, for production of Actiste devices, of SEK 42,287 thousand (41,971). SEK 23 million of receivable plus interest has been impaired during the quarter as a precautionary action as there is uncertainty of the counterparty's ability to pay. The net effect in books is SEK 19.0 million, including impairment of interest and impairment of a debt to the same party. Brighter has commenced legal action in Attunda District Court against Unwrap Finance Nordic AB regarding the claim.



A receivable of SEK 19,751 thousand has over time been written-off by SEK 17,033 thousand as it is exposed to changes in the share price of the underlying share held as security.

At the end of the period the Group had equity of SEK 248,432 thousand (331,093), an equity ratio of 78% (87%).

The Group's long-term interest-bearing debt of SEK 7,237 thousand (10,683) relates to a loan from Almi held by Camanio and the long-term part of leasing liabilities.

The current interest-bearing debt relates to the short-term part of Camanio's debt to Almi and short-term part of leasing liabilities. In Q1 Brighter repaid most interest-bearing debt to external lenders, but in Q2 Brighter borrowed SEK 25 million, of short-term debt from private lenders.

### Cash flow.

At the beginning of the period, the Group had cash of SEK 7,276 thousand (9,340) changing to SEK 15,620 thousand (23,470) by the end of the period.

Cash flow from operating activities after change in working capital amounted to SEK -84,543 thousand (-104,575).

Investments amounted to SEK -30,130 thousand (-72,285), of which investment of SEK -30,138 thousand (-33,375) in intangible assets, and SEK 0 thousand (-2,945) in property, plant and equipment.

Financing of SEK 123,016 thousand (190,990) after costs was raised during the period. New issues contributed SEK 141,975 thousand (201,318) of those.

Total cash flow for the period amounted to SEK 8,343 thousand (14,130).

### Sales.

During the quarter the company communicated that the Actiste® device is compatible with a wider variety of insulin cartridges and can support insulin cartridges from Sanofi and BIOTON S.A. (SciGen Pte. Ltd. – the exclusive distributor of BIOTON products, excluding Poland) This opens up for additional markets with new business opportunities worldwide for Actiste®.

In Q2, Brighter strengthened its position in the Swedish market. The company entered a Proof-of-Concept collaboration with Chronos Care (Chronos Labs AB) to verify Brighter's Actiste® service and evaluate the potential for future commercial collaboration in Sweden with physicians and nurses who work with Chronos Care and its patients. Brighter's User Experience collaboration with two Swedish health centers has during the quarter progressed on track and are expected to provide valuable patient insights that will further support the Actiste® portfolio's commercialization.

In Brazil Brighter received a patent for Actiste® to safely combine Medical Device Directive (MDD) and In-Vitro Diagnostics Directive (IVDD) functionality into one unit. This patent is a key step towards bringing the benefits of the Actiste® diabetes-care solution to Brazil which is expected to be an important future market for Brighter.



In the United Arab Emirates (UAE) the company made progress with several new sales channels. Brighter signed a commercial partnership with DiapointME, a diabetes-oriented digital platform and e-commerce site in the UAE that will market and sell Actiste® and Actiste Mini® on their platform. Two additional commercial partnerships were signed during the quarter with Al Zahra hospital and Prime Medical Center for Actiste® and Actiste® Mini in Dubai. Both are direct sales channels to reach potential Actiste® users in the UAE. Sales of subscriptions through Brighter's local subsidiary will commence once all necessary data storage and telecommunications product and market preparations are completed in the UAE.

In Ghana and Nigeria, the company has continuously focused on working together with its partner distributors on the registration process for the portfolio.

In Qatar the Qatari Communications Regulatory Authority granted Actiste® and Actiste® Mini type approval for the radio transmission element in the device. With this approval for telecom use, Brighter remains focused on completing all the remaining commercialization preparations to bring Brighter's diabetes management platform to patients in need in the region.

Brighter still needs to get certain things in place in its key markets before going live, e.g., ensure data management compliance, finalize administration around cellular connectivity, establish the right partnerships and make sure that the organizational structure is in place. More information about status for each market will be communicated in Q3.

Brighter's subsidiary Nectarine Health initiated discussions with several potential partners in the United States for its AI-based well-being technology, Nectarine Health™ at Home, that focuses on digital care services for the elderly.

Camano, Brighter's other subsidiary, which offers a digital platform for security and supervision launched a pilot project in Tomelilla municipality that aims to digitize elderly care with its digital platform, Camano SmartCare. Camano won a tender to be a supplier of stationery care alarms and alarm reception with Norrtälje Municipality. This marks Camano's first customer within the Adda framework agreement and includes delivery of a digital care platform for alarm reception / management as well as hardware, in the form of care alarms, sensors, and portable alarm buttons.

### Future liquidity position.

The commercialization of Actiste, development and expansion of the Brighter, Camano and Nectarine Health operations requires that the Group has adequate working capital for inventory, build-up of production as well as continued product development. Funding the business is a very important part of the Group's growth strategy and a continuous part of the work of the Group Leadership. In February 2021 Brighter closed a preferential unit issue raising SEK 142 million with a further potential investment of SEK 79 million from warrants exercisable in October 2021. The unit issue together with alternative sources of financing for Nectarine Health and Camano from external investors is expected to fund the business for at least another 12 months. Furthermore, the Board and Group Leadership are continuously



working on and evaluating financing options for the Group to secure the funds and resources needed to pursue the necessary strategy work including financing options such as export financing, contract financing and prepayments from customers.

## Risks.

The principal risks and sources of uncertainty for Brighter include financial risks, such as the future earnings trend, financing, liquidity and currency and credit risks. In addition to market and commercialization risks there are risks associated with Brighter's operations, such as dependencies of suppliers and key personnel, obtaining necessary approval from authorities, product development, patents and intellectual property rights and product responsibility. Further information on the Group risk exposure and risk assessment work can be found in Brighter's 2020 Annual Report pages 29-32 and in Note 20.

## Shareholders.

On June 30<sup>th</sup>, 2021, Brighter AB had about 11,500 shareholders, of which the ten largest represented approximately 24,3% of the capital and votes. The total number of shares amounted to 347,318,433 at the end of the period. The below table illustrates the ten largest shareholders.

	Name	Number of shares	Ownership
1	Försäkringsbolaget Avanza Pension	36 805 976	10,60%
2	DIFF for XDB in the name of owner	10 507 159	3,03%
3	Solokvist AB	5 676 390	1,63%
4	Nordnet Pensionsförsäkring	5 362 101	1,54%
5	Ålandsbanken in the name of owner	5 305 124	1,53%
6	NA Gruppen AB	5 000 000	1,44%
7	Truls Sjöstedt	4 593 673	1,32%
8	Swedbank Försäkring AB	4 428 867	1,28%
9	Ålandsbanken AB, W8iMY	4 117 445	1,19%
10	Thore Andre Nordbö	2 423 514	0,70%

Warrants have been issued on several occasions to employees as incentive and to the shareholders as part of financing solutions. There are currently two listed warrant series; TO5 and TO6, and a small number non-listed warrants distributed as incentive. For further description and status of all the warrant programs please see Note 22 and 25 of Brighter's 2020 Annual Report.





# Submission of interim report.

Stockholm, August 12<sup>th</sup>, 2021  
Brighter AB (publ).

The Board of Directors and the CEO certify that the interim report for the period provides a fair view of the operations, financial position and results of the Parent Company and the Group, and describes material risks and uncertainties facing the Parent Company and the companies included in the Group.

Christer Trägårdh  
Chairman of the Board\*

Emilie Erhardt Winiarski  
Board Member

Åsa Sjöblom Nordgren  
Board Member

Hab El-Assaad  
Board Member

Karin Börjesson O'Connor  
Board Member

Clas Lindbergson  
Board Member

Erik Lissner  
Acting CEO\*

\*Christer Trägårdh was Acting CEO for the report period. Erik Lissner was appointed Acting CEO on the 20<sup>th</sup> of July.

## Financial calendar.

Interim Report Jul-Sep 2021                      2021-11-15

Full year and Interim Report Oct-Dec 2021   2022-02-20

## Review by the auditor.

This interim report has not been reviewed by the company's auditor.





# Financial statements.

## Consolidated statement of comprehensive income.

Amounts in SEK thousand	Note	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020
Net sales		1,599	2,128	3,785	3,840
Capitalized expenditure for development work		15,086	18,895	28,662	27,536
Other operating income		430	509	2,556	1,038
<b>Total</b>		<b>17,116</b>	<b>21,532</b>	<b>35,003</b>	<b>32,415</b>
Raw materials and consumables		-6,016	-1,234	-8,426	-1,814
Other external costs	3	-29,338	-41,339	-58,714	-67,924
Staff costs		-18,373	-18,541	-37,560	-33,439
Depreciation/amortization and write-offs of tangible and intangible assets		-14,889	-6,688	-29,936	-13,210
Other operating costs		-159	-92	-1,525	-436
<b>Operating result</b>		<b>-51,658</b>	<b>-46,362</b>	<b>-101,158</b>	<b>-84,409</b>
Other financial income		825	1,413	1,732	2,015
Financial expenses	5	-22,230	-8,816	-26,692	-8,944
<b>Net financial items</b>		<b>-21,405</b>	<b>-7,403</b>	<b>-24,960</b>	<b>-6,929</b>
Result before income tax		-73,063	-53,765	-126,118	-91,338
Income tax		0	0	0	0
<b>Result for the period</b>		<b>-73,063</b>	<b>-53,765</b>	<b>-126,118</b>	<b>-91,338</b>
Other comprehensive income:					
Translation differences on foreign operations		-10	750	-157	1,699
<b>Total comprehensive income for the period</b>		<b>-73,073</b>	<b>-53,015</b>	<b>-126,275</b>	<b>-89,639</b>
Attributable to the parent company's shareholders		-73,073	-53,015	-126,275	-89,639
Amounts in SEK		Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020
Earnings per share before dilution	4	-0.20	-0.17	-0.40	-0.67
Earnings per share after dilution	4	-0.20	-0.17	-0.40	-0.67



## Consolidated statement of financial position.

Amounts in SEK thousand	30 Jun 2021	30 Jun 2020	Dec 31 2020	
Capitalized expenditure for development work	166,272	182,650	162,309	
Concessions patents licenses trademarks and similar rights	7,993	6,613	7,396	
Goodwill	10,005	10,007	10,007	
Total intangible assets	184,270	199,270	179,711	
Equipment tools and installations	18,161	16,087	19,971	
Right-of-use assets	12,491	18,112	14,986	
Total property, plant and equipment	0	34,199	34,957	
	30,652			
Other long-term securities	12,061	9,944	9,969	
Other long-term receivables	1,647	1,663	1,647	
Total financial assets	13,708	11,607	11,616	
Total fixed assets	228,630	245,075	226,284	
Inventories	16,717	17,222	9,035	
Total inventories	16,717	17,222	9,035	
Accounts receivable	6	529	576	2,524
Current tax assets		3,613	1,182	3,586
Other current receivables	7	45,553	81,788	79,840
Accrued income and costs		7,272	10,000	10,372
Total current receivables		56,967	93,546	96,322
Cash and cash equivalents	6,7	15,620	23,470	7,276
Total current assets		89,303	134,238	112,633
TOTAL ASSETS		317,934	379,314	338,917



## Consolidated statement of financial position cont.

Amounts in SEK thousand	Note	Jun 30 2021	Jun 30 2020	Dec 31 2020
Share capital		17,366	9,952	11,450
Other contributed equity		830,074	639,929	713,205
Retained earnings		-598,907	-318,789	-472,632
<b>Total Equity</b>		<b>248,532</b>	<b>331,093</b>	<b>252,023</b>
Total equity attributable to the parent company's shareholders		248,532	331,093	252,023
Long-term interest-bearing debt		7,237	10,683	8,548
Other long-term liabilities		0,000	127	0
<b>Total long-term liabilities</b>	<b>6,7</b>	<b>7,237</b>	<b>10,810</b>	<b>8,548</b>
Accounts payable	6	8,477	12,794	27,664
Other interest-bearing debt		33,141	0	32,816
Deferred tax liability		2,619	7,315	3,207
Other current liabilities	6	2,701	8,783	4,160
Accruals and deferred income		15,227	8,520	10,499
<b>Total current liabilities</b>		<b>62,164</b>	<b>37,412</b>	<b>78,346</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>317,934</b>	<b>379,314</b>	<b>338,917</b>



## Consolidated statement of changes in equity.

Amounts in SEK thousand	Share Capital	Other contributed equity	Result carried forward (including result for the period)	Total equity
Balance at January 1, 2020	4,806	432,120	-229,150	207,775
Result for the period			-91,338	-91,338
Translation differences on foreign operations			1,699	1,699
Total comprehensive income			-89,639	-89,639
<u>Transactions with shareholders</u>				
New issue for cash	5,033	196,285		201,318
New issue for non-cash consideration	113	12,852		12,965
Issue costs		-1,328		-1,328
Total transactions with shareholders	5,146	207,809	0	212,955
Balance at June 30 2020	9,952	639,929	-318,789	331,093
Balance at January 1, 2021	11,450	713,205	-472,632	252,023
Result for the period			-126,118	-126,118
Translation differences on foreign operations			-157	-157
Total comprehensive income			-126,275	-126,275
<u>Transactions with shareholders</u>				
New issue for cash	4,752	109,303		114,055
New issues for non-cash consideration	1,163	26,757		27,920
Issue costs		-19,191		-19,191
Total transactions with shareholders	5,916	116,869		122,785
Balance at Jun 30 2021	17,366	830,074	-598,907	248,532



## Consolidated statement of cash flows.

Amounts in SEK thousand	Note	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020
Operating result		-51,658	-46,362	-101,158	-84,409
Adjustment for items not included in the cash flow	10	14,835	6,688	29,936	13,210
Interest received		0	5	0	5
Interest paid		-2,945	0	-3,851	-182
Cash flow from operating activities before change in working capital		-39,769	-39,669	-75,073	-71,375
Increase/decrease in inventories		-4,651	-2,257	-7,682	-5,594
Increase/decrease in operating receivables		18,080	4,999	16,172	-4,515
Increase/decrease in operating liabilities		-7,889	-2,186	-17,960	-23,091
Total change in working capital		5,540	0,556	-9,470	-33,200
Cash flow from operating activities		-34,229	-39,113	-84,543	-104,575
Investments in intangible assets		-15,053	-22,570	-30,138	-33,375
Investments in property, plant and equipment		0	-2,498	0	-2,945
Investment in financial assets		0		8	-35,965
Cash flow from investing activities		-15,053	-25,068	-30,130	-72,285
Loans raised/paid		25,000	0	232	-9,000
New share issues and warrants		0	9,186	141,975	201,318
New share issue costs		-3,380	-18	-19,191	-1,328
Cash flow from financing activities		21,620	9,168	123,016	190,990
Cash flow for the period		-27,662	-55,013	8,343	14,130
Opening cash and cash equivalents		43,282	78,483	7,276	9,340
Closing cash and cash equivalents		15,620	23,470	15,620	23,470



## Parent Company income statement.

Amounts in SEK thousand	Note	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020
Sales		0	8	16	8
Capitalized expenditure for development work		6,234	10,750	10,303	15,843
Other operating income		222	99	990	298
Total		6,457	10,857	11,309	16,148
Other external costs		-26,059	-29,307	-46,675	-50,163
Staff costs		-7,172	-6,439	-14,656	-12,474
Depreciation/amortization of tangible and intangible assets		-12,718	-5,103	-25,436	-10,167
Other operating costs		-118	990	-407	651
Total operating costs		-46,068	-39,860	-87,174	-72,152
Operating result		-39,611	-29,003	-75,865	-56,004
Other interest income and similar income		767	1,404	1,606	2,005
Interest expenses and similar expenses	5	-29,741	-8,602	-48,266	-8,667
Total result from financial items		-28,974	-7,198	-46,660	-6,662
Result after financial items		-68,584	-36,201	-122,525	-62,666
Appropriations		0	0	0	0
Tax on result for the period		0	0	0	0
Result for the period		-68,584	-36,201	-122,525	-62,666



## Parent Company balance sheet.

Amounts in SEK thousand	Note	Jun 30 2021	Jun 30 2020	Dec 31 2020
Capitalized expenditure for development work		92,806	135,686	105,989
Concessions, patents, licenses, trademarks and similar rights		7,944	6,621	7,337
Total intangible assets		100,750	142,307	113,326
Equipment, tools and installations		16,832	15,167	18,712
Total property, plant and equipment		16,832	15,167	18,712
Shares in Group companies		64,422	30,754	70,040
Other long-term securities		12,060	9,959	9,960
Other long-term receivables		1,647	1,647	1,647
Total financial assets		78,128	42,360	81,647
Total fixed assets		195,710	195,044	213,684
Inventories		18,701	11,863	8,895
Total inventories		18,701	11,863	8,895
Accounts receivable		0	4	0
Receivable on subsidiary		56,091	65,633	32,420
Other receivables		48,408	82,069	83,201
Accrued income and costs		1,403	6,763	7,290
Total current receivables		105,902	154,469	122,912
Cash at bank and in hand		13,290	17,188	597
Total current assets		137,893	183,520	132,404
TOTAL ASSETS		333,604	383,355	346,088



## Parent Company balance sheet cont.

Amounts in SEK thousand	Note	Jun 30 2021	Jun 30 2020	Dec 31 2020
Share capital		17,366	9,952	11,450
Development expenses fund		92,806	121,030	105,989
Restricted equity		110,172	130,982	117,439
Share premium		830,074	639,929	713,205
Result carried forward		-524,499	-361,749	-320,979
Result for the period		-122,525	-36,201	-216,703
Unrestricted equity		183,050	241,980	175,523
Total equity		293,222	372,962	292,962
Accounts payable		3,796	4,077	19,388
Other interest-bearing debt		27,500	0	26,250
Other liabilities		1,753	644	1,020
Accruals and deferred income		7,332	5,672	6,467
Total current liabilities		40,381	10,394	53,125
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>333,604</b>	<b>383,355</b>	<b>346,088</b>





## Notes.

### Note 1 Accounting policies.

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report.

Significant accounting and valuation principles are detailed in Note 1 in Brighter's 2020 Annual Report. Important estimates and assumptions for accounting purposes can be found in Brighter's 2020 Annual Report in Note 3.

### Note 2 General information.

Brighter AB (publ.) corporate registration number 556736-8591 is a Parent Company registered in Sweden, with its registered office in Stockholm, at Borgarfjordsgatan 18, SE-164 40 Kista, Sweden. The business is located at this address. Brighter develops technical and digital medical devices with a primary area of application in the treatment of diabetes. Brighter AB (publ) has a wholly owned subsidiary, Brighter One AB, the only function of which is to hold warrants as part of the external financing of the Group and as part of the incentive programs. Brighter AB also has a subsidiary in the United Arab Emirates. The name of this government-contract-eligible mainland subsidiary is Brighter Software Trading L.L.C., with management control held by Brighter AB.

From the fourth quarter 2019, Brighter AB has a wholly owned subsidiary in Camanio AB as well as the subsidiary wholly owned by Camanio AB; Bestic AB.

From the first quarter 2020, Brighter AB has a vast majority owned subsidiary in Pink Nectarine Health AB as well as the subsidiaries wholly owned by Pink Nectarine Health AB; Nectarine Health Solutions Limited and Camanio Care Inc (to be name changed). A number of employees own a small number of shares in Pink Nectarine Health AB as part of an incentive plan and the rest is owned by Brighter AB.

Brighter AB is listed on Nasdaq First North Growth Market (BRIG). The Brighter Certified Adviser on Nasdaq First North Growth Market is Eminova Fondkommission AB. Phone: +46 (8) 684 211 00. E-mail: info@eminova.se.

The figures in the report are reported in SEK thousand unless otherwise stated.



### Note 3 Specification of other external costs.

Brighter's other external costs for Jan-Jun 2021 are SEK 47,262 thousand and the rest refers to Nectarine with SEK 8,503 thousand and Camanio with SEK 2,949 thousand.

Other external costs mainly consist of consultancy costs, mostly for FTE consultants. An FTE consultant contributes in every way equal to an employee, but receives payment over invoice.

### Note 4 Earnings per share.

SEK thousand	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020
Result for the period attributable 100% to the parent company's shareholders	-68,584	-36,201	-122,525	-62,666
Number of shares at end of period before dilution *	347,318,433	208,524,781	347,318,433	208,524,781
Number of shares at end of period after dilution *	351,330,485	225,625,578	351,330,485	225,625,578
Weighted average number of shares before dilution *	347,318,433	206,920,800	307,880,802	204,783,944
Earnings per share (SEK) as a weighted average before dilution *	-0.20	-0.17	-0.40	0.67
Earnings per share (SEK) as a weighted average after dilution *	-0.20	-0.17	-0.40	-0.67

\* Average number of shares has been recalculated according to IAS 33 for the periods preceding the completed rights issue in 2021.

### Note 5 Specification of interest expenses and similar expenses.

Group.

SEK thousand	Apr-Jun 2021	Apr-June 2020	Jan-Jun 2021	Jan-Jun 2020
Interest and similar	0,906	1,417	3,851	1,268
Write-off of receivable	3,556	7,399	22,842	7,399
Interest expenses and similar expenses	4,462	8,816	26,692	8,667

Parent.

SEK thousand	Apr-Jun 2021	Apr-June 2020	Jan-Jun 2021	Jan-Jun 2020
Interest and similar	14,085	1,203	5,649	1,268
Write-off of receivable	3,556	7,399	22,842	7,399
Write-off receivable on subsidiary	12,100	0	19,776	0
Interest expenses and similar expenses	29,741	8,602	48,266	8,667



## Note 6 Financial instruments.

### Financial Assets.

SEK thousand	Jun 30 2021	Jun 30 2020	Dec 31 2020
Financial assets valued at fair value over P & L	12,061	9,944	9,969
<b>Assets at acquisition value</b>			
Accounts receivable	529	576	2,524
Depositions on collaboration and rental agreements	1,647	1,663	1,647
Short-term interest-bearing receivable*	2,718	35,352	29,573
Cash and cash equivalents	15,620	23,470	7,276
<b>Total</b>	<b>32,575</b>	<b>71,005</b>	<b>50,989</b>

### Financial Liabilities.

SEK thousand	Jun 30 2021	Jun 30 2020	Dec 31 2020
Long-term interest-bearing debt	7,237	10,810	8,548
Short-term interest-bearing debt	33,141	7,315	32,816
Accounts payable	8,477	12,794	27,664
<b>Total</b>	<b>48,854</b>	<b>30,918</b>	<b>69,027</b>

\*Short-term interest-bearing receivable consists of a receivable of SEK 19,751 thousand. The receivable was written-off by SEK 16,734 thousand as the value of that receivable depends on the share price of the underlying security in shares.

## Note 7 Borrowing and net liabilities.

SEK thousand	Jun 30 2021	Jun 30 2020	Dec 31 2020
<b>Long-term</b>			
Long-term interest-bearing debt	7,237	10,810	8,548
<b>Short-term</b>			
Liabilities relating to interest-bearing debt	33,141	7,315	32,816
<b>Total borrowing</b>	<b>40,378</b>	<b>18,124</b>	<b>41,363</b>
Cash and cash equivalents	15,620	23,470	7,276
<b>Net debt interest-bearing liabilities</b>	<b>24,758</b>	<b>-5,345</b>	<b>34,087</b>
Equity	248,532	331,093	252,023
Debt to equity ratio	10,0%	-1,6%	13,5%



## Note 8 Transactions with affiliated parties.

Transactions with affiliated parties in the form of remuneration, in addition to the Board fee, were carried out with the following Board members. From January 1<sup>st</sup> to Jun 30<sup>th</sup> Christer Trägårdh received SEK 1,029,00 for consultancy services and SEK 24,732 for travel costs as Acting CEO. The amounts are exclusive of VAT. All transactions are carried out on a commercial basis.

## Note 9 Segment information.

Brighter's operating segments consist of Brighter, Camanio and Nectarine Health.

Brighter AB develops mobile solutions in health-tech that facilitates treatment, collects reliable data and enables communication between the patient, relatives and healthcare. Initially, the offer is focused on diabetes.

Camanio AB develops digital solutions for care primarily aimed at the elderly in their home or at retirement homes. The company offers digital service platforms in healthcare, robotics, digital tools and smart technology.

Nectarine Health AB is a Swedish company that develops artificial intelligence solutions within elderly care at home or in nursing homes. The initial offer was, in the form of a bracelet, focused on detecting falls and creating a safe and yet independent life for the elderly person.

### Net sales

There has been a smaller transaction between the segments invoiced at cost of purchases. The revenues from external customers that are reported for the segments to the Group leadership are valued in the same way as in the consolidated income statement.

### Segments assets and liabilities

The segment's assets and liabilities are measured in the same way as in the financial reports. Assets and liabilities are allocated based on the segment's operations.

### Net Sales from customers per segment.

SEK thousand	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020
Segments				
Brighter	0	8	0	8
Camanio	1,046	1,805	3,079	3,271
Nectarine Health	309	482	705	804
Elimination	243	0	0	-243
Total Group Net Sales from customers	1,599	2,295	3,785	3,840



## Earnings before tax per segment.

SEK thousand	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020
<b>Segments</b>				
Brighter	-70,219	28,349	-123,983	-67,135
Camanio	-4,739	5,194	-9,491	-10,052
Nectarine Health	-5,781	3,939	-12,420	-14,150
Elimination	7,676	0	19,776	0
<b>Total Group Earnings before tax Group</b>	<b>-73,063</b>	<b>37,482</b>	<b>-126,118</b>	<b>-91,338</b>

## Assets per segment.

SEK thousand	Jun 30 2021	Jun 30 2020	Dec 31 2020
<b>Segments</b>			
Brighter	342,090	380,071	356,038
Camanio	41,679	39,046	39,628
Nectarine Health	55,336	41,527	44,966
Elimination	-121,170	-81,332	-101,716
<b>Total Assets Group</b>	<b>317,934</b>	<b>379,313</b>	<b>338,917</b>

## Liabilities per segment.

SEK thousand	Jun 30 2021	Jun 30 2020	Dec 31 2020
<b>Segments</b>			
Brighter	49,686	21,760	63,417
Camanio	21,280	36,291	10,980
Nectarine Health	54,791	41,491	50,516
Elimination	-56,356	-51,320	-38,020
<b>Total Liabilities Group</b>	<b>69,401</b>	<b>48,222</b>	<b>86,893</b>

## Note 10 Specification of items not included in the cash flow.

SEK thousand	Apr-Jun 2021	Jan-Mar 2020	Jan-Jun 2021	Jan-Jun 2020
Depreciation/amortization and write-offs of tangible and intangible assets	14,889	6,688	29,936	13,210
<b>Specification of items not included in the cash flow</b>	<b>14,889</b>	<b>6,688</b>	<b>29,936</b>	<b>13,210</b>

## Note 11. Financial key figures.



## Definition of key figures

Net sales	Sales to external customers
Operating profit/loss	Profit/loss before financial items
Profit/loss for the period	Profit/loss after financial items
Earnings per share	Shareholders' equity via the number of outstanding shares before dilution
Operating margin %	Total income via operating profit/loss
Equity ratio %	Shareholders' equity via balance sheet total
Debt to equity ratio	Interest-bearing liabilities in relation to shareholders' equity
Net debt	Interest-bearing liabilities less interest-bearing assets and cash and cash equivalents
Working capital	All current assets minus current liabilities
Net financial items	Financial income minus financial costs
Balance sheet total	Total assets on balance sheet
Other external costs	All costs included in operating profit/loss, except for costs of goods sold, personnel costs and depreciation and share of earnings from associated companies.

# About Brighter.

Brighter addresses common public health challenges through a group of innovation companies. By introducing groundbreaking technology and innovative services, Brighter’s aim is to improve health outcomes and wellbeing amongst the global population and facilitate increased efficiency throughout the healthcare system. Besides the wholly owned and controlled subsidiaries Camanio and Nectarine Health, Brighter has made a strategic investment in digital care provider Accumbo.




## Proactive and data driven medical care.

Brighter has developed unique solutions and services based on patented technology that aim to facilitate more proactive, efficient and data driven medical care, primarily with regard to diabetes under the “Actiste” brand family. The solutions are based on a concept that Brighter refers to as “The Benefit Loop” – a personal, holistic and data centered approach to medical care. The Company has also made a strategic investment in Swedish digital care provider Accumbo, which focuses on hypertension (high blood pressure). Accumbo has successfully launched the Blodtrycksdoktorn [Blood Pressure Doctor] service in Sweden.

## Digital care and support in the home.

During 2019 and 2020, Brighter expanded into the “age-tech” and care sector through the acquisitions of Camanio and Nectarine Health, focusing on innovative technology and services for care and support in the home. Subsidiary Camanio has a broad product portfolio comprising both digital services and physical products enabling a smooth transition to digital care at home. Brighter’s other subsidiary, Nectarine Health, has developed a remote monitoring solution using AI technology to give seniors the confidence to live independently at home for longer, without having to compromise their privacy or dignity, feeling safe and secure knowing that if they experience a health issue, help is always near.





For further information, please contact:

Christer Trägårdh, Acting CEO	Julie Silber, Acting CFO
Phone: +46 70 456 30 02	Phone: +46 79 348 62 77
E-mail: christer.tragardh@brighter.se	E-mail: Julie.silber@brighter.se

This information is such information, as Brighter AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact persons for publication on August 12, 2021 at 09:10 CET.

